Intravenous chimeric anti‑CD20 monoclonal antibody that depletes CD20+ B cells via antibody‑dependent cellular cytotoxicity, complement activation, and apoptosis.
Chimeric anti-CD20 monoclonal antibody that binds CD20 on B cells and depletes them via antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and induction of apoptosis.
YES
DIRECT
Binds CD20 on B cells and recruits immune effectors to kill via Fc-mediated ADCC and complement-dependent cytotoxicity; can also induce apoptosis upon CD20 cross-linking.
Polyclonal antibody preparation that depletes T lymphocytes for induction immunosuppression.
Polyclonal anti–T-lymphocyte IgG that binds multiple T-cell surface antigens and depletes T cells via complement-dependent cytotoxicity and Fc-mediated ADCC, with additional T-cell apoptosis and functional inhibition, producing potent immunosuppression.
YES
DIRECT
ATG contains antibodies that bind CD8α on T cells, triggering complement-dependent lysis and Fc-mediated ADCC, with additional apoptosis, leading to direct depletion of CD8+ T cells.
Type II anti‑CD20 monoclonal antibody engineered to enhance antibody‑dependent cellular cytotoxicity; may be used for post‑response maintenance.
Humanized, glycoengineered type II anti-CD20 IgG1 monoclonal antibody that binds CD20 on B cells and depletes them primarily via enhanced Fc gamma RIIIa (CD16a)-mediated antibody-dependent cellular cytotoxicity and direct, caspase-independent apoptosis, with relatively limited complement activation.
YES
DIRECT
Binds CD20 on B cells and kills via Fc gamma RIIIa (CD16a)-mediated ADCC by NK cells and by inducing direct, caspase-independent apoptosis; complement activation is limited.
Type II anti‑CD20 monoclonal antibody engineered to enhance antibody‑dependent cellular cytotoxicity; may be used for post‑response maintenance.
Humanized, glycoengineered type II anti-CD20 IgG1 monoclonal antibody that binds CD20 on B cells and depletes them primarily via enhanced Fc gamma RIIIa (CD16a)-mediated antibody-dependent cellular cytotoxicity and direct, caspase-independent apoptosis, with relatively limited complement activation.
NO
INDIRECT
Obinutuzumab binds CD20 on B cells; its Fc engages CD16a (FcγRIIIa) on NK cells/monocytes to trigger ADCC, killing CD20+ targets. CD16a-expressing effector cells are activated, not killed.
Type II anti‑CD20 monoclonal antibody engineered to enhance antibody‑dependent cellular cytotoxicity; may be used for post‑response maintenance.
Humanized, glycoengineered type II anti-CD20 IgG1 monoclonal antibody that binds CD20 on B cells and depletes them primarily via enhanced Fc gamma RIIIa (CD16a)-mediated antibody-dependent cellular cytotoxicity and direct, caspase-independent apoptosis, with relatively limited complement activation.
NO
INDIRECT
Obinutuzumab binds CD20 on B cells; its Fc engages Fcγ receptors (e.g., CD16b) on effector cells to trigger ADCC/ADCP against CD20+ targets. CD16b+ cells serve as effectors and are not directly killed.